Search COVID-19 Rapid Resource Center or explore resources sorted by Category or Content Type.
NIH Resource: Drug-Drug Interactions Between Ritonavir-Boosted Nirmatrelvir (Paxlovid) and Concomitant Medications
Ritonavir, a strong cytochrome P450 (CYP) 3A4 inhibitor and a P-glycoprotein inhibitor, is coadministered with nirmatrelvir to increase the blood concentration of nirmatrelvir, thereby making it effective against SARS-CoV-2. Ritonavir may also increase blood concentrations of certain concomitant medications. Because ritonavir-boosted nirmatrelvir (Paxlovid) is the only highly effective oral antiviral for the treatment of COVID-19, drug interactions that can be safely managed should not preclude the use of this medication.
The following link provided is for educational purposes for SCCM members and the general public. Clicking on these links allows users to leave www.sccm.org. The Society does not control the linked sites or the content on those sites. SCCM does not assume any liability for the content or information contained on these linked sites. Further, SCCM does not assume any liability or warrant with respect to the quality, noninfringement, accuracy, completeness, timeliness, or reliability of such linked sites.You should be aware that other internet sites that link to the Site may contain privacy provisions that differ from these policies. To ensure that your privacy is protected, we recommend that you review the privacy policies of other internet sites you visit.